Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01719861|
Recruitment Status : Terminated (Lack of efficacy)
First Posted : November 1, 2012
Results First Posted : April 17, 2017
Last Update Posted : April 17, 2017
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Small Cell Lung Cancer (SCLC) Neuroendocrine Tumors||Drug: Desipramine HCL||Phase 2|
Participants will start desipramine by mouth nightly (QHS) for 6 weeks, with weekly dose escalation. Starting dose will be 25 to 75 mg. The desipramine dose will be escalated until the maximum dose of 450 mg is reached or a maximum safe dose per subject is established.
Dose level may be adjusted (decreased) based on cardiac or general adverse effects. desipramine level will be tapered if the subject experience disease progression, unless physician judges immediate suspension is in the subjects best interest.
Assessments will be conducted every 28 days, and will include ECGs, physicians and blood samples.
One partial and/or complete response will be sufficient to consider a larger clinical trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2a Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors|
|Study Start Date :||October 2012|
|Actual Primary Completion Date :||May 2014|
|Actual Study Completion Date :||May 2015|
Experimental: Desipramine HCl
Desipramine is a tricyclic antidepressant (TCA).
Drug: Desipramine HCL
Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
- Overall Response Rate (ORR) [ Time Frame: 6 weeks ]Overall response rate (ORR) was assessed as the number of patients who achieve either a partial (PR) or complete response (CR) measured by CT scans and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria, divided by the total number of patients treated on the study. CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion.
- Desipramine Maximum Dose [ Time Frame: Up to 6 weeks ]Assessed as the median per patient maximum dose (MD) using intra-patient dose escalation, and reported as the highest dose of desipramine administered continuously for 1 week or greater.
- Median Serum Desipramine Levels During Treatment [ Time Frame: Up to 6 weeks ]
Median serum desipramine levels during treatment is reported as the median of the maximum steady state serum concentration observed in all patients.
Therapeutic concentration of desipramine is 100 to 300 ng/mL, and toxic concentration is > 300 ng/mL.
- Progression-free Survival (PFS), Median [ Time Frame: Up to 5 years from enrollment to radiographic progression or drug discontinuation ]Median PFS was defined as the time from randomization to disease progression (or death if the patient died before progression) calculated using the Kaplan-Meier method.
- Median Overall Survival (OS) [ Time Frame: From start of enrollment until death, no limit ]Median overall survival was defined as time from enrollment to death from any cause calculated using the Kaplan-Meier method.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Metastatic small-cell lung cancer
- Metastatic high-grade neuroendocrine carcinoma of any organ system (high-grade defined by Ki-67 ≥ 20% and/or ≥ 20 mitoses/10 (HPF).
- Received at least one line of prior chemotherapy treatment for metastatic disease.
- Daily chemotherapy must be completed ≥ 2 weeks prior to registration
- Weekly chemotherapy must be completed ≥ 2 weeks prior to registration
- Chemotherapy every 2 weeks must be completed ≥ 3 weeks prior to registration
- Chemotherapy every 3 weeks must be completed ≥ 4 weeks prior to registration
- ECOG Performance Status 0 to 2
- Measurable disease by RECIST 1.1 criteria
- Age at least 18 years
- Estimated life expectancy at least 3 months
- Absolute neutrophil count ≥ 1,500/ mm³
- Platelets ≥ 100,000/mm³
- Hemoglobin ≥ 9 g/dL
- Total bilirubin ≤ 1.5 mg/dL, OR ≤ 2 X ULN if tumor involves the liver
- ALT(SGPT) ≤ 3 X ULN
- Creatinine ≤ 1.5 X ULN
- Creatinine clearance ≥ 45 mL/min/1.73m²) for patients with creatinine levels above institutional normal
- QT interval corrected using Fridericia's method (QTcF) < 450 msec (males) or < 470 msec (females)
- PR < 240 msec
- QRS < 100 msec
- Brain metastases must be asymptomatic and have been adequately treated with radiation finishing at least 1 week prior to initiation of study treatment.
- Ability to understand and the willingness to sign a written informed consent document.
- Clinically-significant ventricular arrhythmia including cardiac arrest
- Myocardial infarction from coronary artery disease within 3 months of study enrollment
- Implantable pacemaker or implantable cardioverter defibrillator
- NYHA Class III or greater congestive heart failure
- Other clinically-significant cardiac disorders
- Family history of long QT syndrome.
- Concomitant or expected treatment with strong inhibitors of cytochrome p450 CYP2D6, specifically including Bupropion; Fluoxetine; or Paroxetine (must be discontinued at least 2 weeks or 5-half lives prior to the initiation of desipramine, whichever is shortest, except fluoxetine which requires at least a 5-week washout period).
- Use of medications known to increase risk of torsades de pointes, including Amiodarone; Arsenic trioxide; Astemizole; Azithromycin; Bepridil; Chloroquine; Chlorpromazine; Cisapride; Citalopram; Clarithromycin; Disopyramide; Dofetilide; Domperidone; Droperidol; Erythromycin; Flecainide; Halofantrine; Haloperidol; Ibutilide; Levomethadyl; Mesoridazine; Methadone; Moxifloxacin; Pentamidine; Pimozide; Probucol; Procainamide; Quinidine; Sotalol; Sparfloxacin; Terfenadine; Thioridazine; Vandetanib
- Other anti-depressant or anti-psychotic medications including selective serotonin re-uptake inhibitors (SSRIs); other tricyclic, monoamine oxidase inhibitors (MAOIs); serotonin-norepinephrine reuptake inhibitors (SNRIs, typical or atypical anti-psychotic)
- Metoclopramide (Reglan) because of increased risk of extrapyrimidal symptoms and neuroleptic malignant syndrome
- Symptomatic orthostatic hypotension despite adequate volume resuscitation.
- Medical history of narrow angle glaucoma
- Bipolar disorder, ongoing or active within the last 5 years
- Suicidal ideation, ongoing or active within the last 5 years
- Suicide attempt, ongoing or active within the last 5 years
- Receiving any other investigational agents
- Any other serious or unstable concomitant systemic disorder that in the opinion of the investigator is incompatible with the clinical study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01719861
|United States, California|
|Stanford University Cancer Institute|
|Stanford, California, United States, 94305|
|Principal Investigator:||Joel W Neal, MD, PhD||Stanford University|
|Responsible Party:||Joel Neal, Assistant Professor, Stanford University|
|Other Study ID Numbers:||
VAR0087 ( Other Identifier: OnCore )
|First Posted:||November 1, 2012 Key Record Dates|
|Results First Posted:||April 17, 2017|
|Last Update Posted:||April 17, 2017|
|Last Verified:||March 2017|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Antidepressive Agents, Tricyclic
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Physiological Effects of Drugs